IL263504A - Taxoid nanoemulsion medicinal preparations, and methods for their targeted use in cancer cells and cancer stem cells - Google Patents

Taxoid nanoemulsion medicinal preparations, and methods for their targeted use in cancer cells and cancer stem cells

Info

Publication number
IL263504A
IL263504A IL263504A IL26350418A IL263504A IL 263504 A IL263504 A IL 263504A IL 263504 A IL263504 A IL 263504A IL 26350418 A IL26350418 A IL 26350418A IL 263504 A IL263504 A IL 263504A
Authority
IL
Israel
Prior art keywords
cells
methods
stem cells
cancer
nanoemulsion compositions
Prior art date
Application number
IL263504A
Other languages
English (en)
Hebrew (he)
Inventor
E Egan James
Ojima Iwao
M Amiji Mansoor
Ivanovna BOTCHKINA Galina
Original Assignee
Targagenix Inc
Univ New York State Res Found
Univ Northeastern
E Egan James
Ojima Iwao
M Amiji Mansoor
Ivanovna BOTCHKINA Galina
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Targagenix Inc, Univ New York State Res Found, Univ Northeastern, E Egan James, Ojima Iwao, M Amiji Mansoor, Ivanovna BOTCHKINA Galina filed Critical Targagenix Inc
Publication of IL263504A publication Critical patent/IL263504A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542Carboxylic acids, e.g. a fatty acid or an amino acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6907Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nanotechnology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Epoxy Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL263504A 2016-06-07 2018-12-04 Taxoid nanoemulsion medicinal preparations, and methods for their targeted use in cancer cells and cancer stem cells IL263504A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662346755P 2016-06-07 2016-06-07
PCT/US2017/036330 WO2017214260A1 (en) 2016-06-07 2017-06-07 Nanoemulsion compositions of taxoid drugs, and methods for the use thereof to target cancer cells and cancer stem cells

Publications (1)

Publication Number Publication Date
IL263504A true IL263504A (en) 2019-01-31

Family

ID=60578981

Family Applications (1)

Application Number Title Priority Date Filing Date
IL263504A IL263504A (en) 2016-06-07 2018-12-04 Taxoid nanoemulsion medicinal preparations, and methods for their targeted use in cancer cells and cancer stem cells

Country Status (9)

Country Link
US (3) US10206875B2 (enExample)
EP (1) EP3463299A4 (enExample)
JP (1) JP7518604B2 (enExample)
CN (2) CN116019768A (enExample)
AU (1) AU2017277497B2 (enExample)
CA (1) CA3026412A1 (enExample)
IL (1) IL263504A (enExample)
MX (1) MX2018015112A (enExample)
WO (1) WO2017214260A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3463299A4 (en) * 2016-06-07 2020-01-15 Targagenix, Inc. TAXOID NANOEMULSION COMPOSITIONS, AND METHODS OF USE THEREOF FOR TARGETING CANCER CELLS AND CANCER STEM CELLS
JP7450888B2 (ja) * 2017-12-20 2024-03-18 タルガジェニックス,インコーポレイテッド がんにおける免疫療法との併用タキソイドナノエマルジョン
JP7610208B2 (ja) * 2019-03-22 2025-01-08 インテグレイテッド ナノセラピューティクス インコーポレイテッド 足場部分から調製した脂質結合体
WO2021081326A1 (en) * 2019-10-25 2021-04-29 Amgen Inc. Compositions and methods for minimizing protein loss at low protein concentrations
CA3157484A1 (en) * 2019-11-05 2021-05-14 Ulagaraj Selvaraj Nanoparticles comprising prodrugs stabilized by albumin for treatment of cancer and other diseases
CN111004195B (zh) * 2019-12-03 2022-01-28 沈阳药科大学 卡巴他赛弱碱性衍生物及其制剂
CN114317398B (zh) * 2020-09-27 2024-03-01 中国科学院分子细胞科学卓越创新中心 Gli1和EpCAM基因共同标记的肝祖细胞群及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6426367B1 (en) * 1999-09-09 2002-07-30 Efa Sciences Llc Methods for selectively occluding blood supplies to neoplasias
CA2544128A1 (en) * 2003-10-30 2005-05-12 The Research Foundation Of State University Of New York Taxoid-fatty acid conjugates and pharmaceutical compositions thereof
US8557861B2 (en) * 2004-09-28 2013-10-15 Mast Therapeutics, Inc. Low oil emulsion compositions for delivering taxoids and other insoluble drugs
US20070148194A1 (en) * 2005-11-29 2007-06-28 Amiji Mansoor M Novel nanoemulsion formulations
CN102105134B (zh) * 2008-07-23 2013-08-14 印度血清及疫苗有限公司 稳定的可注射的水包油型多烯紫杉醇纳米乳剂
US20100021471A1 (en) * 2008-07-25 2010-01-28 Brookhaven Science Associates, Llc Carbon nanotube-based drug delivery systems and methods of making same
US20140105829A1 (en) * 2012-10-15 2014-04-17 Nemucore Medical Innovations, Inc. Therapeutic nanoemulsion formulation for the targeted delivery of docetaxel and methods of making and using the same
PL3157508T3 (pl) * 2014-06-19 2021-05-17 Solural Pharma ApS Związki lipofilowe w postaci stałej dawkowane doustnie
US10736842B2 (en) * 2014-06-25 2020-08-11 Synergia Bio Sciences Private Limited Pharmaceutical oil-in-water nano-emulsion
EP3463299A4 (en) * 2016-06-07 2020-01-15 Targagenix, Inc. TAXOID NANOEMULSION COMPOSITIONS, AND METHODS OF USE THEREOF FOR TARGETING CANCER CELLS AND CANCER STEM CELLS
JP7450888B2 (ja) * 2017-12-20 2024-03-18 タルガジェニックス,インコーポレイテッド がんにおける免疫療法との併用タキソイドナノエマルジョン

Also Published As

Publication number Publication date
USRE50096E1 (en) 2024-08-27
US20180028442A1 (en) 2018-02-01
WO2017214260A1 (en) 2017-12-14
US20250009658A1 (en) 2025-01-09
AU2017277497B2 (en) 2023-05-04
CN116019768A (zh) 2023-04-28
NZ748915A (en) 2024-09-27
CA3026412A1 (en) 2017-12-14
US10206875B2 (en) 2019-02-19
MX2018015112A (es) 2019-09-09
CN109562065A (zh) 2019-04-02
EP3463299A1 (en) 2019-04-10
JP7518604B2 (ja) 2024-07-18
EP3463299A4 (en) 2020-01-15
JP2019523226A (ja) 2019-08-22
AU2017277497A1 (en) 2018-12-20

Similar Documents

Publication Publication Date Title
ZA202004557B (en) Modulatory polynucleotides
IL263504A (en) Taxoid nanoemulsion medicinal preparations, and methods for their targeted use in cancer cells and cancer stem cells
IL269444B (en) New modified indazoles, methods for their production, pharmaceutical preparations containing the new modified indazoles, and the use of the new modified indazoles in the production of drugs
IL261963A (en) Antibodies, pharmaceutical preparations and methods
IL259246A (en) Preparations containing pharmaceutical substances and methods of using them
EP3258941A4 (en) Treatment of cancers and hematopoietic stem cell disorders privileged by cxcl12-cxcr4 interaction
ZA201605175B (en) Antibodies, pharmaceutical compositions and uses thereof
IL263341A (en) Stem cell material, compounds and methods of use
IL261623A (en) Stem cells expressing mesenchymal and neuronal markers, compositions containing them and methods for their preparation
IL290114A (en) Pharmaceutical preparations, their preparation and uses
LT3223796T (lt) Farmacinės kompozicijos, jų gamyba ir panaudojimo būdai
IL252397A0 (en) Pharmaceutical preparations, their preparation and uses
EP3111951A4 (en) Anticancer functional peptide for inhibiting proliferation of cancer stem cell, and use thereof
GB201613078D0 (en) Stem cells and cancer
LT3229843T (lt) Farmacinė kompozicija, jos paruošimo būdas ir naudojimas
EP3151826A4 (en) Omega-3 compositions, dosage forms, and methods of use
PT3503885T (pt) Composição farmacêutica e métodos de utilização
IL249860A0 (en) Pharmaceutical preparations, methods for their preparation and their use for the treatment of cancer
IL258242B (en) Preparations and methods for inhibiting cancer stem cells
HK40006913A (en) Nanoemulsion compositions of taxoid drugs, and methods for the use thereof to target cancer cells and cancer stem cells
GB201520226D0 (en) Pharmaceutical compositions comprising of hetero-bicyclic derivatives, and methodsof use thereof.
HK40003869A (en) Novel rna construct and methods of use thereof for enhancing the therapeutic effects of cytotoxic cells and stem cells
GB201415969D0 (en) Pharmaceutical compositions comprising of hetero-bicyclic derivatives, and methods of use thereof
HK1258652A1 (en) Methods and compositions for the treatment of head and neck cancer
HK1234671A1 (en) Omega-3 compositions, dosage forms, and methods of use